Erlotinib Erlocip 150mg

Erlotinib monotherapy is indicated for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) in patients who have failed at least one prior chemotherapy regimen.

In two multicenter, randomized, placebo-controlled Phase III trials, results demonstrated that erlotinib in combination with platinum-based chemotherapy regimens (carboplatin + paclitaxel; or gemcitabine + cisplatin) as first-line treatment for patients with locally advanced or metastatic NSCLC did not provide additional clinical benefit compared to platinum-based chemotherapy alone; therefore, it is not recommended for use as first-line treatment in these settings.

Erlotinib monotherapy may be used as maintenance therapy for patients with locally advanced or metastatic NSCLC whose disease has remained stable following 4 cycles of platinum-based first-line chemotherapy. This indication is based on a randomized, double-blind, placebo-controlled study. Currently, clinical study data comparing the use of erlotinib as maintenance therapy (following non-progression after first-line chemotherapy) versus its use after disease progression are not available.

Clinical studies investigating the use of this product as first-line treatment in patients with EGFR mutations are currently ongoing. Prescribing physicians are advised to determine the appropriate treatment option by comprehensively considering the latest research advancements regarding this product and similar agents, as well as the patient's individual clinical status.

Dosage and Administration:

This product must be used under the supervision of a physician experienced in the use of such agents.

The recommended dose of erlotinib monotherapy for NSCLC is 150 mg/day, taken at least 1 hour before or 2 hours after a meal. Treatment should be continued until disease progression or the occurrence of intolerable toxicity. There is no evidence to suggest that continuing treatment after disease progression provides clinical benefit to the patient.

Dose Adjustment:

If a patient develops new-onset acute or progressive pulmonary symptoms—such as dyspnea, cough, or fever—erlotinib therapy should be temporarily suspended pending diagnostic evaluation. If Interstitial Lung Disease (ILD) is confirmed, erlotinib should be permanently discontinued, and appropriate treatment should be administered. Erlotinib should be discontinued in patients who develop hepatic failure or gastrointestinal perforation. Patients who are dehydrated and at risk of renal failure, those suffering from severe bullous, blistering, or exfoliative skin disorders, and those with acute or worsening eye conditions should interrupt or discontinue the use of erlotinib.

Globally, nearly 500,000 new cases of cervical cancer are diagnosed annually; it has now become the third most common cancer among women. Although cervical cancer screening has been widely implemented and vaccines against the human papillomavirus (HPV) are commercially available, cervical cancer remains a significant public health concern. Currently, the standard treatment regimen for cervical cancer consists of cisplatin-based chemoradiotherapy. However, a recent clinical study suggests that erlotinib (Tarceva)—an EGFR inhibitor—holds promise for improving the treatment of cervical cancer.

A Phase II clinical trial was designed to evaluate the potential of combining the EGFR inhibitor erlotinib (Tarceva) with chemoradiotherapy in 36 women with cervical cancer. The enrolled patients had Stage IIB to IIIB squamous cell carcinoma of the cervix, had received no prior treatment, and possessed an Eastern Cooperative Oncology Group (ECOG) performance status ranging from 0 to 2. Patients began receiving erlotinib at a dose of 150 mg/day one week prior to treatment initiation; this was followed by a regimen combining cisplatin and external-beam radiotherapy, and subsequently, brachytherapy. The median duration of treatment was 77 days, with a median follow-up period of 59.3 months. The overall treatment regimen was well-tolerated, and 34 patients (94.4%) achieved a complete response.

The findings reported by Nogueira-Rodrigues et al. indicate that the combination of erlotinib (Tarceva) and cisplatin-based chemoradiotherapy was generally well-tolerated, with 94.4% of patients achieving a complete response. At the two-year mark, 91.7% of the women were still alive, and 80.6% remained disease-free. By the three-year mark, 80% of the women were still alive, and 73.8% had experienced no disease progression. However, larger-scale clinical trials are required to determine whether this therapeutic approach can be established as the standard regimen for advanced-stage cervical cancer. **Product Specifications**

**Product Name:** Tarceva (Erlotinib) | Erlocip 150mg

**Common Name:** Tarceva

**Composition:** Erlotinib Hydrochloride 150mg

**Dosage Form:** Tablets

**Specification:** 30 Tablets

**Manufacturer:** Cipla Pharmaceuticals

**Indications:** Erlotinib monotherapy is indicated for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) in patients who have previously failed at least one chemotherapy regimen.

Clinical studies regarding the use of this product as a first-line treatment for patients with EGFR mutations are currently ongoing. Prescribing physicians are advised to determine the appropriate treatment choice by comprehensively considering the latest research advancements regarding this product and similar agents, as well as the patient's individual condition.

**Dosage and Administration:** This product must be used under the supervision of a physician experienced in the use of such medications.

The recommended dose of Erlotinib monotherapy for non-small cell lung cancer is 150 mg per day, taken at least 1 hour before or 2 hours after a meal. Treatment should be continued until disease progression or the occurrence of intolerable toxicity. There is no evidence to suggest that continuing treatment after disease progression provides any clinical benefit to the patient.